Home 2018-07-05T11:36:59+00:00

for a Brighter Tomorrow

JOIN MAILING LIST

PRESENTATION

PIPELINE

INVESTORS

ABOUT US

Oramed Pharmaceuticals (NASDAQ: ORMP) has developed an innovative technology to transform injectable treatments into oral therapies.

Oramed’s flagship product, an oral insulin capsule, has the potential to better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles.

Oramed’s oral insulin is currently in advanced clinical trials under the US FDA for both type 1 and type 2 diabetes.

In addition to oral insulin, the company’s proprietary POD™ technology can be used to orally administer a number of protein-based therapies, which are available only via injection.

PRESS RELEASES

Oramed Patent in Europe to be Granted for Oral Delivery of Proteins

January 28th, 2020|Comments Off on Oramed Patent in Europe to be Granted for Oral Delivery of Proteins

Protease inhibitor is a key component of platform technology that protects [...]

Oramed Elects Dr. Alexander Fleming to Scientific Advisory Board

January 23rd, 2020|Comments Off on Oramed Elects Dr. Alexander Fleming to Scientific Advisory Board

NEW YORK, Jan. 23, 2020 Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: [...]